Carboplatin Dosing and Administration in Adult Cancer Patients
Carboplatin should be dosed using AUC-based formula dosing (Calvert formula) targeting AUC 5-6 for most combination regimens, administered as a 30-60 minute IV infusion without mandatory pre- or post-hydration, with appropriate antiemetic prophylaxis based on moderate emetic risk classification. 1
Dosing Strategy
AUC-Based Dosing (Preferred Method)
Use the Calvert formula for all patients to ensure predictable drug exposure and minimize toxicity risk 1:
Total Dose (mg) = Target AUC × (GFR + 25)
- Target AUC 5-6 for combination therapy (standard regimens with paclitaxel) 2
- Target AUC 4-5 for previously treated patients receiving single-agent therapy 1
- Target AUC 6-7 for untreated patients receiving single-agent therapy 3
Critical point: The dose is calculated in mg, not mg/m² when using the Calvert formula 1
Body Surface Area Dosing (Alternative)
If AUC-based dosing is not feasible:
- 300-360 mg/m² every 3-4 weeks for combination therapy 1
- 400 mg/m² every 4 weeks for single-agent therapy in good-risk patients 1
- 270 mg/m² every 4 weeks for poor-risk patients (poor performance status, bone metastases, third-space fluid) 4
Important caveat: BSA-based dosing leads to significant over- or underdosing in patients with abnormal renal function, potentially resulting in either excessive toxicity or therapeutic failure 5, 6
Renal Function Considerations
GFR Estimation
Use CKD-EPI equation for GFR estimation rather than Cockcroft-Gault, as it provides more clinically appropriate dosing and reduces risk of overdosing in higher body weight patients and underdosing in lower body weight patients 5. The Cockcroft-Gault formula historically used can result in up to 17% of patients receiving doses ≥20% higher than appropriate 5.
Dose Adjustments for Renal Impairment
For patients with creatinine clearance <60 mL/min using BSA dosing 1:
| Creatinine Clearance | Recommended Dose |
|---|---|
| 41-59 mL/min | 250 mg/m² |
| 16-40 mL/min | 200 mg/m² |
| <15 mL/min | Insufficient data; avoid use |
Patients with CrCl <60 mL/min are at 25% risk of severe myelosuppression even with dose adjustments 1.
Administration Schedule and Infusion
Standard Regimens
Three-week cycle (most common) 2:
- Carboplatin AUC 5-6 IV over 30-60 minutes on Day 1
- Repeat every 21 days for 6 cycles
- Typically combined with paclitaxel 175 mg/m² over 3 hours
Weekly regimen (alternative, particularly for elderly/frail patients) 2, 7:
- Carboplatin AUC 2 IV over 30 minutes on Days 1,8,15
- One week off (Day 21)
- Repeat every 28 days for 18 weeks total
- Better tolerated with lower neuropathy, neutropenia, and alopecia rates 7
Infusion Duration
Administer over 15-60 minutes 1. Longer infusions (60 minutes) are preferred for higher doses or when combined with other agents.
Hydration Requirements
No mandatory pre- or post-treatment hydration or forced diuresis is required for standard carboplatin dosing 1, 8.
Exceptions requiring hydration 8:
- Patients with pre-existing renal impairment
- High-dose carboplatin (≥800 mg/m²)
- Combination with other nephrotoxic agents
This represents a major practical advantage over cisplatin, which always requires aggressive hydration 8.
Antiemetic Prophylaxis
Carboplatin AUC ≥4 (Moderate-High Emetic Risk)
Use 3-drug combination on Day 1 9, 10:
- NK₁ receptor antagonist (aprepitant, fosaprepitant, rolapitant, or netupitant)
- 5-HT₃ receptor antagonist (ondansetron 8 mg IV/PO, granisetron 1 mg IV or 2 mg PO, or palonosetron 0.25 mg IV)
- Dexamethasone 12 mg (if using aprepitant/fosaprepitant/netupitant) or 20 mg (if using rolapitant)
No routine antiemetics needed on Days 2-3 unless other emetogenic agents are used 9, 10
Carboplatin AUC <4 (Moderate Emetic Risk)
Use 2-drug combination on Day 1 only 9, 10:
- 5-HT₃ receptor antagonist
- Dexamethasone 8 mg
Monitoring Requirements
Before Each Cycle
Do not administer until 1:
- Neutrophil count ≥2,000/μL
- Platelet count ≥100,000/μL
Baseline Assessment
- Complete blood count with differential
- Comprehensive metabolic panel (renal function, electrolytes)
- Calculated GFR using CKD-EPI equation 5
- Performance status assessment
During Treatment
- Weekly CBC to monitor nadir (typically occurs Days 14-21) 1
- Renal function monitoring as clinically indicated
- Magnesium levels if symptoms develop (hypomagnesemia can occur) 4
Dose Modifications for Toxicity
Based on nadir counts from previous cycle 1:
| Platelets | Neutrophils | Dose Adjustment |
|---|---|---|
| >100,000 | >2,000 | Increase to 125% |
| 50,000-100,000 | 500-2,000 | No change |
| <50,000 | <500 | Reduce to 75% |
Special Populations
Elderly Patients
Formula dosing based on GFR is essential in elderly patients due to age-related decline in renal function 1. The weekly regimen (AUC 2 on Days 1,8,15 every 28 days) may be particularly appropriate for patients ≥75 years, offering similar efficacy with better tolerability 7.
Patients with Poor Performance Status
Consider reduced initial dosing (270 mg/m² if using BSA method) or lower target AUC (4-5) 1, 4. The weekly regimen is also a reasonable alternative 7.
Common Pitfalls to Avoid
Using Cockcroft-Gault instead of CKD-EPI for GFR estimation leads to inappropriate dosing in 20-37% of patients 5
Capping GFR at 125 mL/min when using Calvert formula may result in underdosing in patients with excellent renal function 6
Unnecessary hydration protocols add cost and time without benefit at standard doses 8
Administering next cycle with inadequate count recovery significantly increases risk of severe myelosuppression 1
Using BSA-based dosing in renally impaired patients without adjustment leads to predictable overdosing and toxicity 1, 6
Failing to adjust antiemetic regimen based on carboplatin AUC—higher AUC (≥4) requires NK₁ antagonist addition 9, 10